世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Global Primary Biliary Cholangitis Therapeutics Market 2024-2028


Global Primary Biliary Cholangitis Therapeutics Market 2024-2028 The primary biliary cholangitis therapeutics market is forecasted to grow by USD 346.85 mn during 2023-2028, accelerating at a CAGR... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechNavio
テクナビオ
2023年11月9日 US$2,500
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
151 英語

日本語のページは自動翻訳を利用し作成しています。


 

Summary

Global Primary Biliary Cholangitis Therapeutics Market 2024-2028
The primary biliary cholangitis therapeutics market is forecasted to grow by USD 346.85 mn during 2023-2028, accelerating at a CAGR of 8.75% during the forecast period. The report on the primary biliary cholangitis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by emergence of telehealth and remote monitoring, rising investments and developments in healthcare industry, and increase in product launches in primary biliary cholangitis therapeutics market.
Technavio's primary biliary cholangitis therapeutics market is segmented as below:
By Type
• Primary drug
• Secondary drug
By Distribution Channel
• Drug stores and retail pharmacies
• Hospital pharmacies
• Online pharmacies
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the increasing demand for R&D due to government healthcare expenditure as one of the prime reasons driving the primary biliary cholangitis therapeutics market growth during the next few years. Also, increasing geriatric population and rise in the R and D investments in primary biliary cholangitis therapeutics by manufacturers will lead to sizable demand in the market.
The report on the primary biliary cholangitis therapeutics market covers the following areas:
• Primary biliary cholangitis therapeutics market sizing
• Primary biliary cholangitis therapeutics market forecast
• Primary biliary cholangitis therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/primary-biliary-cholangitis-therapeutics-market-industry-analysis
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

ページTOPに戻る


Table of Contents

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global primary biliary cholangitis therapeutics market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
o 4.2 Type Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
o 4.3 Distribution Channel Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 Primary drug - Market size and forecast 2023-2028
o Exhibit 34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
o 6.4 Secondary drug - Market size and forecast 2023-2028
o Exhibit 38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Type
o Exhibit 42: Market opportunity by Type ($ million)
o Exhibit 43: Data Table on Market opportunity by Type ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
o Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 46: Chart on Comparison by Distribution Channel
o Exhibit 47: Data Table on Comparison by Distribution Channel
o 7.3 Drug stores and retail pharmacies - Market size and forecast 2023-2028
o Exhibit 48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
o Exhibit 49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
o Exhibit 50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
o 7.4 Hospital pharmacies - Market size and forecast 2023-2028
o Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
o 7.5 Online pharmacies - Market size and forecast 2023-2028
o Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 60: Market opportunity by Distribution Channel ($ million)
o Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 Canada - Market size and forecast 2023-2028
o Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
o 9.9 Germany - Market size and forecast 2023-2028
o Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.10 China - Market size and forecast 2023-2028
o Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
o 9.11 UK - Market size and forecast 2023-2028
o Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 111: Abbott Laboratories - Overview
o Exhibit 112: Abbott Laboratories - Business segments
o Exhibit 113: Abbott Laboratories - Key news
o Exhibit 114: Abbott Laboratories - Key offerings
o Exhibit 115: Abbott Laboratories - Segment focus
o 12.4 AbbVie Inc.
o Exhibit 116: AbbVie Inc. - Overview
o Exhibit 117: AbbVie Inc. - Product / Service
o Exhibit 118: AbbVie Inc. - Key news
o Exhibit 119: AbbVie Inc. - Key offerings
o 12.5 Alkem Laboratories Ltd.
o Exhibit 120: Alkem Laboratories Ltd. - Overview
o Exhibit 121: Alkem Laboratories Ltd. - Business segments
o Exhibit 122: Alkem Laboratories Ltd. - Key news
o Exhibit 123: Alkem Laboratories Ltd. - Key offerings
o Exhibit 124: Alkem Laboratories Ltd. - Segment focus
o 12.6 Eli Lilly and Co.
o Exhibit 125: Eli Lilly and Co. - Overview
o Exhibit 126: Eli Lilly and Co. - Product / Service
o Exhibit 127: Eli Lilly and Co. - Key news
o Exhibit 128: Eli Lilly and Co. - Key offerings
o 12.7 GENFIT SA
o Exhibit 129: GENFIT SA - Overview
o Exhibit 130: GENFIT SA - Product / Service
o Exhibit 131: GENFIT SA - Key offerings
o 12.8 Glenmark Pharmaceuticals Ltd.
o Exhibit 132: Glenmark Pharmaceuticals Ltd. - Overview
o Exhibit 133: Glenmark Pharmaceuticals Ltd. - Product / Service
o Exhibit 134: Glenmark Pharmaceuticals Ltd. - Key offerings
o 12.9 ICE S.p.a.
o Exhibit 135: ICE S.p.a. - Overview
o Exhibit 136: ICE S.p.a. - Product / Service
o Exhibit 137: ICE S.p.a. - Key offerings
o 12.10 Intercept Pharmaceuticals Inc.
o Exhibit 138: Intercept Pharmaceuticals Inc. - Overview
o Exhibit 139: Intercept Pharmaceuticals Inc. - Product / Service
o Exhibit 140: Intercept Pharmaceuticals Inc. - Key offerings
o 12.11 Ipsen Pharma
o Exhibit 141: Ipsen Pharma - Overview
o Exhibit 142: Ipsen Pharma - Business segments
o Exhibit 143: Ipsen Pharma - Key offerings
o Exhibit 144: Ipsen Pharma - Segment focus
o 12.12 Leeford Healthcare Ltd.
o Exhibit 145: Leeford Healthcare Ltd. - Overview
o Exhibit 146: Leeford Healthcare Ltd. - Key offerings
o 12.13 NGM Biopharmaceuticals Inc.
o Exhibit 147: NGM Biopharmaceuticals Inc. - Overview
o Exhibit 148: NGM Biopharmaceuticals Inc. - Key offerings
o 12.14 Novartis AG
o Exhibit 149: Novartis AG - Overview
o Exhibit 150: Novartis AG - Business segments
o Exhibit 151: Novartis AG - Key offerings
o Exhibit 152: Novartis AG - Segment focus
o 12.15 Teva Pharmaceutical Industries Ltd.
o Exhibit 153: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 154: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 155: Teva Pharmaceutical Industries Ltd. - Key news
o Exhibit 156: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 157: Teva Pharmaceutical Industries Ltd. - Segment focus
o 12.16 Viatris Inc.
o Exhibit 158: Viatris Inc. - Overview
o Exhibit 159: Viatris Inc. - Business segments
o Exhibit 160: Viatris Inc. - Key news
o Exhibit 161: Viatris Inc. - Key offerings
o Exhibit 162: Viatris Inc. - Segment focus
o 12.17 Zydus Lifesciences Ltd.
o Exhibit 163: Zydus Lifesciences Ltd. - Overview
o Exhibit 164: Zydus Lifesciences Ltd. - Business segments
o Exhibit 165: Zydus Lifesciences Ltd. - Key offerings
o Exhibit 166: Zydus Lifesciences Ltd. - Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 167: Inclusions checklist
o Exhibit 168: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 169: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 170: Research methodology
o Exhibit 171: Validation techniques employed for market sizing
o Exhibit 172: Information sources
o 13.5 List of abbreviations
o Exhibit 173: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Type - Market share 2023-2028 (%)
Exhibits31: Data Table on Type - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Type ($ million)
Exhibits43: Data Table on Market opportunity by Type ($ million)
Exhibits44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits45: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by Distribution Channel
Exhibits47: Data Table on Comparison by Distribution Channel
Exhibits48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Distribution Channel ($ million)
Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Abbott Laboratories - Overview
Exhibits112: Abbott Laboratories - Business segments
Exhibits113: Abbott Laboratories - Key news
Exhibits114: Abbott Laboratories - Key offerings
Exhibits115: Abbott Laboratories - Segment focus
Exhibits116: AbbVie Inc. - Overview
Exhibits117: AbbVie Inc. - Product / Service
Exhibits118: AbbVie Inc. - Key news
Exhibits119: AbbVie Inc. - Key offerings
Exhibits120: Alkem Laboratories Ltd. - Overview
Exhibits121: Alkem Laboratories Ltd. - Business segments
Exhibits122: Alkem Laboratories Ltd. - Key news
Exhibits123: Alkem Laboratories Ltd. - Key offerings
Exhibits124: Alkem Laboratories Ltd. - Segment focus
Exhibits125: Eli Lilly and Co. - Overview
Exhibits126: Eli Lilly and Co. - Product / Service
Exhibits127: Eli Lilly and Co. - Key news
Exhibits128: Eli Lilly and Co. - Key offerings
Exhibits129: GENFIT SA - Overview
Exhibits130: GENFIT SA - Product / Service
Exhibits131: GENFIT SA - Key offerings
Exhibits132: Glenmark Pharmaceuticals Ltd. - Overview
Exhibits133: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibits134: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibits135: ICE S.p.a. - Overview
Exhibits136: ICE S.p.a. - Product / Service
Exhibits137: ICE S.p.a. - Key offerings
Exhibits138: Intercept Pharmaceuticals Inc. - Overview
Exhibits139: Intercept Pharmaceuticals Inc. - Product / Service
Exhibits140: Intercept Pharmaceuticals Inc. - Key offerings
Exhibits141: Ipsen Pharma - Overview
Exhibits142: Ipsen Pharma - Business segments
Exhibits143: Ipsen Pharma - Key offerings
Exhibits144: Ipsen Pharma - Segment focus
Exhibits145: Leeford Healthcare Ltd. - Overview
Exhibits146: Leeford Healthcare Ltd. - Key offerings
Exhibits147: NGM Biopharmaceuticals Inc. - Overview
Exhibits148: NGM Biopharmaceuticals Inc. - Key offerings
Exhibits149: Novartis AG - Overview
Exhibits150: Novartis AG - Business segments
Exhibits151: Novartis AG - Key offerings
Exhibits152: Novartis AG - Segment focus
Exhibits153: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits154: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits155: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits156: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits157: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits158: Viatris Inc. - Overview
Exhibits159: Viatris Inc. - Business segments
Exhibits160: Viatris Inc. - Key news
Exhibits161: Viatris Inc. - Key offerings
Exhibits162: Viatris Inc. - Segment focus
Exhibits163: Zydus Lifesciences Ltd. - Overview
Exhibits164: Zydus Lifesciences Ltd. - Business segments
Exhibits165: Zydus Lifesciences Ltd. - Key offerings
Exhibits166: Zydus Lifesciences Ltd. - Segment focus
Exhibits167: Inclusions checklist
Exhibits168: Exclusions checklist
Exhibits169: Currency conversion rates for US$
Exhibits170: Research methodology
Exhibits171: Validation techniques employed for market sizing
Exhibits172: Information sources
Exhibits173: List of abbreviations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


TechNavio社はどのような調査会社ですか?


テクナビオ(TechNavio)は英国ロンドンに本社をおく幅広い市場を調査対象とする調査会社インフィニティリサーチ社(Infiniti Research)の調査レポート出版部門です。データリソースはT... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/09/19 10:28

144.64 円

160.77 円

193.27 円

ページTOPに戻る